FDA, GLP-1 and type 2 diabetes

FDA approves generic GLP-1 drug to treat type 2 diabetes
The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), significantly improving access to diabetes
FDA Approves Generic GLP-1 Medicine For Diabetes Treatment
The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a
FDA says shortage of GLP-1 drug tirzepatide is over
The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes/weight-loss med tirzepatide is over.
FDA Approves Second Generic Daily GLP-1 Drug for T2D
The US Food and Drug Administration approved a generic once-daily injectable version of the glucagon-like peptide-1 receptor agonist liraglutide.
FDA Approves First Medication for Obstructive Sleep Apnea
By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP machines remain the first-line treatment.
FDA approves generic in same class as Ozempic for diabetes. Could it ease shortage, price?
The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could be used for in adults and children 10 and up. The new drug, sold under the name Victoza and made by Hikma Pharmaceuticals USA Inc., follows the approval of the generic GLP-1 exanatide last month, sold under the name Byetta.
FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes
FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes
FDA Says Shortages of GLP-1 Drugs Mounjaro and Zepbound Are Over
Tirzepatide, the main ingredient in Mounjaro and Zepbound, is no longer in shortage, according to the U.S. Food and Drug Administration. Compounded copycat drugs containing tirzepatide, many sold by online pharmacies, will no longer be allowed.
FDA approves GLP-1 generic for Type 2 diabetes
The U.S. Food and Drug Administration (FDA) has approved a generic daily injectable for the GLP-1 medication for patients who are 10 years old and up with Type 2 diabetes. The liraglutide injection, which is currently in shortage and sold under the brand name Victoza,
FDA rejects GLP-2 drug candidate
Zealand Pharma's GLP-2 drug candidate fails to gain FDA approval due to request for additional trial to confirm efficacy and safety.
The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
There’s still no generic Ozempic, but a lower-priced daily injected GLP-1 is coming
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...
JD Supra4d
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide ...